TerminatedNCT03279731
Binge Eating Liraglutide Intervention
Medication studyAges 21–70United StatesEating disorders
Understand this study
Who could participate?
Listed age limits: 21 years to 70 years.
What will I do during this study?
The protocol includes: Completing questionnaires.
- Listed locations
- PhiladelphiaSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: September 29, 2017
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 36
- Sponsor
- Kelly Allison
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 21 Years to 70 Years
- Official registry ID
- NCT03279731
- Official title
Show the full official title
Liraglutide 3.0mg/d for the Treatment of Binge Eating Disorder
Recruitment & locations
TerminatedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Philadelphia
Interested in joining this study?
Questions about this study
What will I need to do?
You will complete questionnaires.
Who is behind this study?
The study sponsor is Kelly Allison.
Does this study involve medication?
Yes. The study involves medication, including Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml and Placebo.
Who can participate?
Listed age limits: 21 years to 70 years.
Is this study still recruiting?
The registry lists this study as terminated.
